EQL Pharma

47.30 SEK

-3.47 %

Less than 1K followers

EQL

NASDAQ Stockholm

Biotechnology & Pharmaceuticals

Health Care

Overview

Financials & Estimates

Ownership

Dividend

Investor consensus

-3.47 %

-6.89 %

-23.71 %

-18.17 %

-18.87 %

-39.97 %

+51.12 %

+52.58 %

+780.04 %

EQL Pharma operates in the pharmaceutical industry and focuses on the development, manufacturing and distribution of generic medicines. The company's products are aimed at healthcare institutions and patients who need cost-effective treatment options. The business is global with a primary presence in Europe, North America and Asia. EQL Pharma was founded in 2006 and is headquartered in Lund, Sweden.

Market cap

1.4B SEK

Turnover

1.03M SEK

Revenue

373.52M

EBIT %

18.04 %

P/E

31.96

Dividend yield-%

-

Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar

8.5

2026

Annual report '26

20.8

2026

General meeting '26

All

Press releases

3rd party

ShowingAll content types

Press release4/27/2026, 11:12 AM

EQL Pharma in process of recruiting new Chief Supply Chain Officer (CSCO)

Press release4/22/2026, 11:01 AM

Invitation to presentation in connection with EQL Pharma's year-end report, fourth quarter, 2025/26

Press release4/20/2026, 4:58 AM

DNB Carnegie Access: EQL Pharma: Recovery continues, but near-term headwinds – Q4 preview

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account

Followings and notifications on followed companies

Analyst comments and recommendations

Stock comparison tool & other popular tools

Press release3/27/2026, 3:48 PM

EQL Pharma CEO sells shares to finance capital gains tax from option redemption

Press release3/25/2026, 9:36 AM

EQL Pharma: Mellozzan® (melatonin) has been approved in Italy

Regulatory press release2/12/2026, 12:22 PM

EQL Pharma: Nomination committee for the 2026 Annual General Meeting

Press release2/4/2026, 8:19 AM

DNB Carnegie Access: EQL Pharma: Solid Q3 with branded-driven EBIT beat – worst behind it

Press release2/3/2026, 1:25 PM

DNB Carnegie Access: EQL Pharma: Q3 2025/26 initial: Beat driven by strong branded sales

Regulatory press release2/3/2026, 1:15 PM

Bulletin from the extraordinary general meeting in EQL Pharma AB on 3 February 2026

Regulatory press release2/3/2026, 11:30 AM

EQL Pharma: Interim Report April - December 2025

Press release1/27/2026, 6:15 AM

DNB Carnegie Access: EQL Pharma: From reset to recovery – Q3 2025/26 preview

Press release1/15/2026, 10:40 AM

Invitation to presentation in connection with EQL Pharma's interim report, third quarter, 2025/26

Regulatory press release1/7/2026, 12:29 PM

Notice of extraordinary general meeting in EQL Pharma AB

Regulatory press release12/4/2025, 9:00 AM

EQL Pharma recruits Anne D Jensen as new Chief Sales Officer (CSO) and Carl Lindgren leaves his position as Chief Business Development Officer (CBDO)

Regulatory press release12/3/2025, 1:36 PM

EQL Pharma recruits Allan Sylvest Aasberg as new Chief Financial Officer (CFO)

Regulatory press release11/17/2025, 12:57 PM

EQL Pharma AB (publ) publishes prospectus and applies for admission to trading of bonds on the corporate bond list of Nasdaq Stockholm

Press release11/14/2025, 12:49 PM

EQL Pharma: Methenamine Hippurate (branded as Cystohipp©) have gained marketing approval in Germany

Press release11/6/2025, 7:08 AM

DNB Carnegie Access: EQL Pharma: Branded sales and restocking to drive recovery

Press release11/5/2025, 7:41 AM

DNB Carnegie Access: EQL Pharma: Weak set of numbers, as expected – Q2 initial take

Regulatory press release11/5/2025, 6:00 AM

EQL Pharma: Interim Report April - September 2025

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.